...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later
【24h】

Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later

机译：低流行国家的8-10岁乙肝疫苗接种者中的抗体动力学以及5或10年后给予加强剂量的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Few data are available concerning the persistence of anti-HBs and the effect of booster doses given several years post-vaccination against hepatitis B during preadolescence. The objective of this open-labelled clinical trial was to evaluate the persistence of antibodies after vaccination with three paediatric doses of Engerix-B at the age of 8-10 years and the effect of a booster dose given 5 (Group Y5) or 10 (Group Y10) years later. Anti-HBs were measured before and one month post-primary vaccination, then 5 and 10 years later, before the booster dose, as well as one month and I year post-booster. The anamnestic response was defined as a >= fourfold increase of anti-HBs post-booster (>= 10IU/L) when compared to prebooster. Ten years post-primary vaccination, 559 of the 652 initially randomized subjects (86%) were eligible for analysis. Group Y5, 5 years post-booster results: 99% of subjects had detectable levels of antibodies and 96% a titer >= 10IU/L. The anti-HBs GMTs decreased from 114,489IU/L one month post-booster to 3354 IU/L 5 years later. Group Y10 results: 10 years post-primary vaccination 96% of subjects had a detectable level of anti-HBs and 85% were above the threshold of 10 IU/L The GMTs one month post-booster were 31,030 IU/L The challenge with a booster demonstrated an anamnestic response in 99% of subjects in group Y5 and 100% of subjects in group Y10. All subjects were anti-HBc negative. The booster doses were well tolerated. The excellent anamnestic response observed after the booster dose demonstrates the persistence of immunity in virtually all young adults vaccinated at the age of 8-10 with three paediatric doses of Engerix-B. (C) 2009 Elsevier Ltd. All rights reserved.
机译：几乎没有关于抗HBs的持久性以及在青春期前接种乙肝疫苗后数年给予加强剂量的影响的数据。这项公开标签的临床试验的目的是评估在8-10岁时接种三种儿科剂量的Engerix-B疫苗接种后抗体的持久性，以及给予5（Y5组）或10（增强组）的加强剂量的效果Y10组）几年后。在初次接种疫苗之前和之后，一个月之后，然后在加强剂量之前的5年和10年，以及加强接种后一个月和一年后，测量抗HBs。记忆消除反应被定义为与加强前相比，加强后抗-HBs升高> = 4倍（> = 10IU / L）。初次接种疫苗十年后，在652名最初随机分组的受试者中有559名（86％）有资格进行分析。 Y5组，加强效果后5年：99％的受试者具有可检测的抗体水平，而96％的滴度> = 10IU / L。抗-HBs GMTs从加强后一个月的114,489IU / L降至五年后的3354 IU / L。 Y10组结果：初次接种疫苗10年后，有96％的受试者具有可检测到的抗HBs水平，而85％的受试者的阈值高于10 IU / L。加强免疫后1个月的GMT为31,030 IU / L。加强免疫组在Y5组的99％的受试者和Y10组的100％的受试者中表现出记忆消除反应。所有受试者均为抗-HBc阴性。加强剂量耐受良好。加强剂量后观察到的出色的记忆消除反应表明，几乎所有在8-10岁时接种了3种儿科Engerix-B疫苗的年轻人都具有免疫力。 （C）2009 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号